Cargando…

Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma

Background—There are currently no effective therapies for diffuse malignant peritoneal mesothelioma (DMPM) patients with disease recurrence. In this study, we investigated the biology of DMPM by analyzing the EGFR family, Axl, and MET, in order to assess the presence of cross-talk between these rece...

Descripción completa

Detalles Bibliográficos
Autores principales:	Belfiore, Antonino, Busico, Adele, Bozzi, Fabio, Brich, Silvia, Dallera, Elena, Conca, Elena, Capone, Iolanda, Gloghini, Annunziata, Volpi, Chiara C., Cabras, Antonello D., Pilotti, Silvana, Baratti, Dario, Guaglio, Marcello, Deraco, Marcello, Kusamura, Shigeki, Perrone, Federica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888071/ https://www.ncbi.nlm.nih.gov/pubmed/31752449 http://dx.doi.org/10.3390/ijms20225817

Ejemplares similares

A2AR Expression and Immunosuppressive Environment Independent of KRAS and GNAS Mutations in Pseudomyxoma Peritonei
por: Kusamura, Shigeki, et al.
Publicado: (2023)

Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework
por: Bozzi, Fabio, et al.
Publicado: (2016)

Commment on the review entitled “A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer” by Chiva LM and Gonzalez-Martin A.
por: Deraco, Marcello, et al.
Publicado: (2015)

Survivin is Highly Expressed and Promotes Cell Survival in Malignant Peritoneal Mesothelioma
por: Zaffaroni, Nadia, et al.
Publicado: (2007)

Diagnostic and Therapeutic Pathway in Diffuse Malignant Peritoneal Mesothelioma
por: Kusamura, Shigeki, et al.
Publicado: (2023)

Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types
por: Tazzari, Marcella, et al.
Publicado: (2018)

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study
por: Pietrantonio, Filippo, et al.
Publicado: (2016)

Correlation between biological and mechanical properties of extracellular matrix from colorectal peritoneal metastases in human tissues
por: Lorenc, Ewelina, et al.
Publicado: (2023)

New transcriptional-based insights into the pathogenesis of desmoplastic small round cell tumors (DSRCTs)
por: Negri, Tiziana, et al.
Publicado: (2017)

Mesothelioma
por: Deraco, Marcello
Publicado: (2021)

Sunitinib-induced morpho-functional changes and drug effectiveness in malignant solitary fibrous tumours
por: Spagnuolo, Rosalin D., et al.
Publicado: (2016)

Decellularized extracellular matrix as scaffold for cancer organoid cultures of colorectal peritoneal metastases
por: Varinelli, Luca, et al.
Publicado: (2022)

Preliminary results of a program for the implementation of laparoscopic colorectal surgery in an Italian comprehensive cancer center during the COVID-19 pandemic
por: Baratti, D., et al.
Publicado: (2022)

miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma
por: El Bezawy, Rihan, et al.
Publicado: (2022)

Breast implant associated anaplastic large cell lymphoma: Evidence for an efficient diagnostic workup
por: Vittoria, Laura, et al.
Publicado: (2023)

Prevalence of BRCA homopolymeric indels in an ION Torrent-based tumour-to-germline testing workflow in high-grade ovarian carcinoma
por: Azzollini, Jacopo, et al.
Publicado: (2023)

MIF/CD74 axis is a target for novel therapies in colon carcinomatosis
por: Bozzi, Fabio, et al.
Publicado: (2017)

Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma
por: Sciarrillo, Rocco, et al.
Publicado: (2018)

Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production
por: Mogavero, Angela, et al.
Publicado: (2017)

AKT1 and BRAF mutations in pediatric aggressive fibromatosis
por: Meazza, Cristina, et al.
Publicado: (2016)

Force Sensing on Cells and Tissues by Atomic Force Microscopy
por: Holuigue, Hatice, et al.
Publicado: (2022)

Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples
por: Capone, Iolanda, et al.
Publicado: (2022)

CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts
por: De Cesare, Michelandrea, et al.
Publicado: (2016)

Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model
por: Azzollini, Jacopo, et al.
Publicado: (2022)

Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism
por: El Bezawy, Rihan, et al.
Publicado: (2017)

Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma
por: Minna, Emanuela, et al.
Publicado: (2020)

SMO mutations confer poor prognosis in malignant pleural mesothelioma
por: Signorelli, Diego, et al.
Publicado: (2020)

Pulmonary adenocarcinoma with mucin production modulates phenotype according to common genetic traits: a reappraisal of mucinous adenocarcinoma and colloid adenocarcinoma
por: Sonzogni, Angelica, et al.
Publicado: (2017)

A Pilot Study of the Predictive Potential of Chemosensitivity and Gene Expression Assays Using Circulating Tumour Cells from Patients with Recurrent Ovarian Cancer
por: Guadagni, Stefano, et al.
Publicado: (2020)

Primary central nervous system lymphoma
por: Gloghini, Annunziata, et al.
Publicado: (2015)

Epstein Barr Virus-Associated Hodgkin Lymphoma
por: Carbone, Antonino, et al.
Publicado: (2018)

Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O(6)-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial
por: Morano, Federica, et al.
Publicado: (2022)

β‐Catenin in desmoid‐type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression
por: Colombo, Chiara, et al.
Publicado: (2017)

The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial–mesenchymal transition, and immune response
por: Devecchi, Andrea, et al.
Publicado: (2018)

Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin
por: De Cesare, Michelandrea, et al.
Publicado: (2015)

Diagnostic and Therapeutic Algorithm for Appendiceal Tumors and Pseudomyxoma Peritonei: A Consensus of the Peritoneal Malignancies Oncoteam of the Italian Society of Surgical Oncology (SICO)
por: Vaira, Marco, et al.
Publicado: (2023)

Comments on: Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study
por: Batista, Thales Paulo, et al.
Publicado: (2019)

Identification of a gene expression driven progression pathway in myxoid liposarcoma
por: De Cecco, Loris, et al.
Publicado: (2014)

Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care
por: Vingiani, Andrea, et al.
Publicado: (2023)

Complexity of progranulin mechanisms of action in mesothelioma
por: Ventura, Elisa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_frq8fpsdfkqqb2v5tsg49enau9